South Korean biopharmaceutical company Celltrion said it would invest at least $1 billion to acquire a plant from Eli Lilly ...

Celltrion signed a $330 million deal on Tuesday to acquire an Eli Lilly and Company biopharmaceutical plant in New Jersey, securing a U.S. production base as part of its strategy to reduce tariff ...

Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC ...

After teasing its position in a bidding contest for a large-scale drug substance plant in the U.S. this summer, South Korea’s Celltrion has sealed the deal. | Celltrion—which specializes in biosimilar ...

The report stated that Celltrion, on Tuesday, announced its U.S. subsidiary signed a contract on Saturday to acquire 100 per ...

Celltrion buys Lilly US plant, secures local production and tariff relief Celltrion to expand U.S. biologics site with 700 ...

Celltrion, South Korea's leading biopharmaceutical company, said on Tuesday its US subsidiary has signed a deal to acquire a ...

Celltrion said Tuesday it has signed a deal to acquire Eli Lilly’s biopharmaceutical manufacturing plant in Branchburg, New ...

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of ...

Investing.com-- South Korea’s Celltrion Inc (KS:068270) said on Tuesday it has signed a deal to buy Eli Lilly’s (NYSE:LLY) biologics manufacturing facility in the U.S. for about 460 billion won ($330 ...